nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—CHRNA5—thyroid gland—thyroid cancer	0.0161	0.0596	CbGeAlD
Galantamine—CHRNG—trachea—thyroid cancer	0.0146	0.0539	CbGeAlD
Galantamine—CHRNA5—head—thyroid cancer	0.0143	0.0529	CbGeAlD
Galantamine—CHRNB3—head—thyroid cancer	0.013	0.0481	CbGeAlD
Galantamine—CHRNB2—saliva-secreting gland—thyroid cancer	0.0115	0.0425	CbGeAlD
Galantamine—CHRNA6—head—thyroid cancer	0.0108	0.0401	CbGeAlD
Galantamine—CHRNG—head—thyroid cancer	0.0102	0.0378	CbGeAlD
Galantamine—CHRNA5—lymph node—thyroid cancer	0.01	0.0371	CbGeAlD
Galantamine—CHRNB4—head—thyroid cancer	0.00985	0.0364	CbGeAlD
Galantamine—CHRNA7—neck—thyroid cancer	0.00935	0.0346	CbGeAlD
Galantamine—CHRND—thyroid gland—thyroid cancer	0.00914	0.0338	CbGeAlD
Galantamine—CHRNB2—trachea—thyroid cancer	0.00888	0.0328	CbGeAlD
Galantamine—CHRNA10—head—thyroid cancer	0.00867	0.0321	CbGeAlD
Galantamine—CHRNA1—thyroid gland—thyroid cancer	0.00763	0.0282	CbGeAlD
Galantamine—CHRNB2—thyroid gland—thyroid cancer	0.00702	0.026	CbGeAlD
Galantamine—CHRFAM7A—trachea—thyroid cancer	0.00696	0.0257	CbGeAlD
Galantamine—CHRNA1—head—thyroid cancer	0.00677	0.025	CbGeAlD
Galantamine—CHRNA2—thyroid gland—thyroid cancer	0.00633	0.0234	CbGeAlD
Galantamine—CHRNB2—head—thyroid cancer	0.00623	0.023	CbGeAlD
Galantamine—CHRNA10—lymph node—thyroid cancer	0.00607	0.0224	CbGeAlD
Galantamine—CHRNA3—head—thyroid cancer	0.00604	0.0223	CbGeAlD
Galantamine—CHRNB1—thyroid gland—thyroid cancer	0.00589	0.0218	CbGeAlD
Galantamine—CHRNA2—head—thyroid cancer	0.00562	0.0208	CbGeAlD
Galantamine—CHRFAM7A—thyroid gland—thyroid cancer	0.00551	0.0204	CbGeAlD
Galantamine—CHRNB1—head—thyroid cancer	0.00523	0.0193	CbGeAlD
Galantamine—ACHE—thyroid gland—thyroid cancer	0.00511	0.0189	CbGeAlD
Galantamine—CHRFAM7A—head—thyroid cancer	0.00489	0.0181	CbGeAlD
Galantamine—CHRNA7—thyroid gland—thyroid cancer	0.00445	0.0164	CbGeAlD
Galantamine—CHRNB2—lymph node—thyroid cancer	0.00436	0.0161	CbGeAlD
Galantamine—CHRNA3—lymph node—thyroid cancer	0.00423	0.0156	CbGeAlD
Galantamine—CHRNA7—head—thyroid cancer	0.00395	0.0146	CbGeAlD
Galantamine—CHRNA4—head—thyroid cancer	0.00389	0.0144	CbGeAlD
Galantamine—CHRNB1—lymph node—thyroid cancer	0.00366	0.0135	CbGeAlD
Galantamine—BCHE—trachea—thyroid cancer	0.00317	0.0117	CbGeAlD
Galantamine—ACHE—lymph node—thyroid cancer	0.00317	0.0117	CbGeAlD
Galantamine—BCHE—thyroid gland—thyroid cancer	0.00251	0.00928	CbGeAlD
Galantamine—BCHE—head—thyroid cancer	0.00223	0.00823	CbGeAlD
Galantamine—Shock—Sorafenib—thyroid cancer	0.00164	0.00236	CcSEcCtD
Galantamine—Nervous system disorder—Sorafenib—thyroid cancer	0.00164	0.00235	CcSEcCtD
Galantamine—Dizziness—Vandetanib—thyroid cancer	0.00164	0.00235	CcSEcCtD
Galantamine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00164	0.00235	CcSEcCtD
Galantamine—Blood urea increased—Epirubicin—thyroid cancer	0.00163	0.00235	CcSEcCtD
Galantamine—Skin disorder—Sorafenib—thyroid cancer	0.00162	0.00233	CcSEcCtD
Galantamine—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.0016	0.0023	CcSEcCtD
Galantamine—Hiccups—Doxorubicin—thyroid cancer	0.0016	0.0023	CcSEcCtD
Galantamine—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.0016	0.0023	CcSEcCtD
Galantamine—Anorexia—Sorafenib—thyroid cancer	0.00159	0.00229	CcSEcCtD
Galantamine—Cramps of lower extremities—Epirubicin—thyroid cancer	0.00159	0.00228	CcSEcCtD
Galantamine—Vomiting—Vandetanib—thyroid cancer	0.00157	0.00226	CcSEcCtD
Galantamine—Bladder pain—Epirubicin—thyroid cancer	0.00156	0.00225	CcSEcCtD
Galantamine—Melaena—Doxorubicin—thyroid cancer	0.00156	0.00225	CcSEcCtD
Galantamine—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00156	0.00225	CcSEcCtD
Galantamine—Rash—Vandetanib—thyroid cancer	0.00156	0.00224	CcSEcCtD
Galantamine—BCHE—lymph node—thyroid cancer	0.00156	0.00577	CbGeAlD
Galantamine—Dermatitis—Vandetanib—thyroid cancer	0.00156	0.00224	CcSEcCtD
Galantamine—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00155	0.00223	CcSEcCtD
Galantamine—Headache—Vandetanib—thyroid cancer	0.00155	0.00223	CcSEcCtD
Galantamine—Cystitis—Doxorubicin—thyroid cancer	0.00155	0.00222	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00152	0.00219	CcSEcCtD
Galantamine—Hypertonia—Epirubicin—thyroid cancer	0.00152	0.00218	CcSEcCtD
Galantamine—Blood urea increased—Doxorubicin—thyroid cancer	0.00151	0.00217	CcSEcCtD
Galantamine—CYP2D6—head—thyroid cancer	0.00148	0.00546	CbGeAlD
Galantamine—Nausea—Vandetanib—thyroid cancer	0.00147	0.00211	CcSEcCtD
Galantamine—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.00147	0.00211	CcSEcCtD
Galantamine—Dyspepsia—Sorafenib—thyroid cancer	0.00147	0.00211	CcSEcCtD
Galantamine—Decreased appetite—Sorafenib—thyroid cancer	0.00145	0.00209	CcSEcCtD
Galantamine—Bladder pain—Doxorubicin—thyroid cancer	0.00145	0.00208	CcSEcCtD
Galantamine—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00144	0.00208	CcSEcCtD
Galantamine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00144	0.00207	CcSEcCtD
Galantamine—Fatigue—Sorafenib—thyroid cancer	0.00144	0.00207	CcSEcCtD
Galantamine—Constipation—Sorafenib—thyroid cancer	0.00143	0.00205	CcSEcCtD
Galantamine—Vascular purpura—Epirubicin—thyroid cancer	0.0014	0.00202	CcSEcCtD
Galantamine—Hypertonia—Doxorubicin—thyroid cancer	0.0014	0.00202	CcSEcCtD
Galantamine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00137	0.00196	CcSEcCtD
Galantamine—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00134	0.00192	CcSEcCtD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—NRG1—thyroid cancer	0.00133	0.0392	CbGpPWpGaD
Galantamine—Body temperature increased—Sorafenib—thyroid cancer	0.00132	0.0019	CcSEcCtD
Galantamine—Abdominal pain—Sorafenib—thyroid cancer	0.00132	0.0019	CcSEcCtD
Galantamine—Renal impairment—Epirubicin—thyroid cancer	0.00132	0.0019	CcSEcCtD
Galantamine—Purpura—Epirubicin—thyroid cancer	0.0013	0.00187	CcSEcCtD
Galantamine—Vascular purpura—Doxorubicin—thyroid cancer	0.0013	0.00187	CcSEcCtD
Galantamine—Cardiac failure—Epirubicin—thyroid cancer	0.00129	0.00185	CcSEcCtD
Galantamine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00128	0.00184	CcSEcCtD
Galantamine—Lethargy—Epirubicin—thyroid cancer	0.00128	0.00184	CcSEcCtD
Galantamine—Pain in extremity—Epirubicin—thyroid cancer	0.00126	0.00181	CcSEcCtD
Galantamine—Hypersensitivity—Sorafenib—thyroid cancer	0.00123	0.00177	CcSEcCtD
Galantamine—Renal impairment—Doxorubicin—thyroid cancer	0.00122	0.00176	CcSEcCtD
Galantamine—Purpura—Doxorubicin—thyroid cancer	0.00121	0.00173	CcSEcCtD
Galantamine—Asthenia—Sorafenib—thyroid cancer	0.0012	0.00172	CcSEcCtD
Galantamine—Cardiac failure—Doxorubicin—thyroid cancer	0.00119	0.00171	CcSEcCtD
Galantamine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00119	0.0017	CcSEcCtD
Galantamine—Lethargy—Doxorubicin—thyroid cancer	0.00119	0.0017	CcSEcCtD
Galantamine—Ataxia—Epirubicin—thyroid cancer	0.00118	0.0017	CcSEcCtD
Galantamine—Dehydration—Epirubicin—thyroid cancer	0.00117	0.00168	CcSEcCtD
Galantamine—Pain in extremity—Doxorubicin—thyroid cancer	0.00116	0.00167	CcSEcCtD
Galantamine—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00115	0.00165	CcSEcCtD
Galantamine—Abdominal pain upper—Epirubicin—thyroid cancer	0.00115	0.00165	CcSEcCtD
Galantamine—Hypokalaemia—Epirubicin—thyroid cancer	0.00114	0.00164	CcSEcCtD
Galantamine—Diarrhoea—Sorafenib—thyroid cancer	0.00114	0.00164	CcSEcCtD
Galantamine—Gastritis—Epirubicin—thyroid cancer	0.00111	0.0016	CcSEcCtD
Galantamine—Muscular weakness—Epirubicin—thyroid cancer	0.00111	0.00159	CcSEcCtD
Galantamine—Dizziness—Sorafenib—thyroid cancer	0.0011	0.00159	CcSEcCtD
Galantamine—Ataxia—Doxorubicin—thyroid cancer	0.00109	0.00157	CcSEcCtD
Galantamine—Dysphagia—Epirubicin—thyroid cancer	0.00109	0.00156	CcSEcCtD
Galantamine—Dehydration—Doxorubicin—thyroid cancer	0.00108	0.00155	CcSEcCtD
Galantamine—Vomiting—Sorafenib—thyroid cancer	0.00106	0.00153	CcSEcCtD
Galantamine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00106	0.00153	CcSEcCtD
Galantamine—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00106	0.00153	CcSEcCtD
Galantamine—Hypokalaemia—Doxorubicin—thyroid cancer	0.00106	0.00152	CcSEcCtD
Galantamine—Rash—Sorafenib—thyroid cancer	0.00105	0.00151	CcSEcCtD
Galantamine—Dermatitis—Sorafenib—thyroid cancer	0.00105	0.00151	CcSEcCtD
Galantamine—Headache—Sorafenib—thyroid cancer	0.00105	0.0015	CcSEcCtD
Galantamine—Bronchitis—Epirubicin—thyroid cancer	0.00104	0.0015	CcSEcCtD
Galantamine—Gastritis—Doxorubicin—thyroid cancer	0.00103	0.00148	CcSEcCtD
Galantamine—Muscular weakness—Doxorubicin—thyroid cancer	0.00102	0.00147	CcSEcCtD
Galantamine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00101	0.00145	CcSEcCtD
Galantamine—Dysphagia—Doxorubicin—thyroid cancer	0.001	0.00144	CcSEcCtD
Galantamine—Pollakiuria—Epirubicin—thyroid cancer	0.001	0.00144	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—RET—thyroid cancer	0.000994	0.0293	CbGpPWpGaD
Galantamine—Nausea—Sorafenib—thyroid cancer	0.000992	0.00143	CcSEcCtD
Galantamine—Weight decreased—Epirubicin—thyroid cancer	0.000982	0.00141	CcSEcCtD
Galantamine—Hyperglycaemia—Epirubicin—thyroid cancer	0.000979	0.00141	CcSEcCtD
Galantamine—Pneumonia—Epirubicin—thyroid cancer	0.000973	0.0014	CcSEcCtD
Galantamine—Bronchitis—Doxorubicin—thyroid cancer	0.000966	0.00139	CcSEcCtD
Galantamine—Renal failure—Epirubicin—thyroid cancer	0.000951	0.00137	CcSEcCtD
Galantamine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000949	0.00136	CcSEcCtD
Galantamine—Urinary tract infection—Epirubicin—thyroid cancer	0.000941	0.00135	CcSEcCtD
Galantamine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000933	0.00134	CcSEcCtD
Galantamine—Pollakiuria—Doxorubicin—thyroid cancer	0.000928	0.00133	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000924	0.0272	CbGpPWpGaD
Galantamine—Haematuria—Epirubicin—thyroid cancer	0.000923	0.00133	CcSEcCtD
Galantamine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000915	0.00132	CcSEcCtD
Galantamine—Epistaxis—Epirubicin—thyroid cancer	0.000913	0.00131	CcSEcCtD
Galantamine—Weight decreased—Doxorubicin—thyroid cancer	0.000909	0.00131	CcSEcCtD
Galantamine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000906	0.0013	CcSEcCtD
Galantamine—Pneumonia—Doxorubicin—thyroid cancer	0.000901	0.00129	CcSEcCtD
Galantamine—Bradycardia—Epirubicin—thyroid cancer	0.000884	0.00127	CcSEcCtD
Galantamine—Renal failure—Doxorubicin—thyroid cancer	0.00088	0.00127	CcSEcCtD
Galantamine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000878	0.00126	CcSEcCtD
Galantamine—Haemoglobin—Epirubicin—thyroid cancer	0.000873	0.00126	CcSEcCtD
Galantamine—Rhinitis—Epirubicin—thyroid cancer	0.000871	0.00125	CcSEcCtD
Galantamine—Urinary tract infection—Doxorubicin—thyroid cancer	0.00087	0.00125	CcSEcCtD
Galantamine—Hepatitis—Epirubicin—thyroid cancer	0.000869	0.00125	CcSEcCtD
Galantamine—Haemorrhage—Epirubicin—thyroid cancer	0.000869	0.00125	CcSEcCtD
Galantamine—Urinary tract disorder—Epirubicin—thyroid cancer	0.000858	0.00123	CcSEcCtD
Galantamine—Oedema peripheral—Epirubicin—thyroid cancer	0.000856	0.00123	CcSEcCtD
Galantamine—Haematuria—Doxorubicin—thyroid cancer	0.000854	0.00123	CcSEcCtD
Galantamine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000854	0.00123	CcSEcCtD
Galantamine—Urethral disorder—Epirubicin—thyroid cancer	0.000852	0.00122	CcSEcCtD
Galantamine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000847	0.00122	CcSEcCtD
Galantamine—Epistaxis—Doxorubicin—thyroid cancer	0.000845	0.00121	CcSEcCtD
Galantamine—Visual impairment—Epirubicin—thyroid cancer	0.000837	0.0012	CcSEcCtD
Galantamine—Bradycardia—Doxorubicin—thyroid cancer	0.000818	0.00118	CcSEcCtD
Galantamine—Eye disorder—Epirubicin—thyroid cancer	0.000812	0.00117	CcSEcCtD
Galantamine—Tinnitus—Epirubicin—thyroid cancer	0.00081	0.00116	CcSEcCtD
Galantamine—Haemoglobin—Doxorubicin—thyroid cancer	0.000808	0.00116	CcSEcCtD
Galantamine—Flushing—Epirubicin—thyroid cancer	0.000806	0.00116	CcSEcCtD
Galantamine—Cardiac disorder—Epirubicin—thyroid cancer	0.000806	0.00116	CcSEcCtD
Galantamine—Rhinitis—Doxorubicin—thyroid cancer	0.000806	0.00116	CcSEcCtD
Galantamine—Haemorrhage—Doxorubicin—thyroid cancer	0.000804	0.00116	CcSEcCtD
Galantamine—Hepatitis—Doxorubicin—thyroid cancer	0.000804	0.00116	CcSEcCtD
Galantamine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000794	0.00114	CcSEcCtD
Galantamine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000792	0.00114	CcSEcCtD
Galantamine—CHRNB2—Circadian rythm related genes—NKX2-1—thyroid cancer	0.000791	0.0233	CbGpPWpGaD
Galantamine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00079	0.00114	CcSEcCtD
Galantamine—Angiopathy—Epirubicin—thyroid cancer	0.000788	0.00113	CcSEcCtD
Galantamine—Urethral disorder—Doxorubicin—thyroid cancer	0.000788	0.00113	CcSEcCtD
Galantamine—Immune system disorder—Epirubicin—thyroid cancer	0.000785	0.00113	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—RET—thyroid cancer	0.000782	0.0231	CbGpPWpGaD
Galantamine—Arrhythmia—Epirubicin—thyroid cancer	0.000776	0.00112	CcSEcCtD
Galantamine—Visual impairment—Doxorubicin—thyroid cancer	0.000775	0.00111	CcSEcCtD
Galantamine—Mental disorder—Epirubicin—thyroid cancer	0.000761	0.00109	CcSEcCtD
Galantamine—Malnutrition—Epirubicin—thyroid cancer	0.000756	0.00109	CcSEcCtD
Galantamine—Eye disorder—Doxorubicin—thyroid cancer	0.000751	0.00108	CcSEcCtD
Galantamine—Tinnitus—Doxorubicin—thyroid cancer	0.000749	0.00108	CcSEcCtD
Galantamine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000746	0.00107	CcSEcCtD
Galantamine—Flushing—Doxorubicin—thyroid cancer	0.000746	0.00107	CcSEcCtD
Galantamine—Flatulence—Epirubicin—thyroid cancer	0.000745	0.00107	CcSEcCtD
Galantamine—Tension—Epirubicin—thyroid cancer	0.000742	0.00107	CcSEcCtD
Galantamine—Dysgeusia—Epirubicin—thyroid cancer	0.000741	0.00106	CcSEcCtD
Galantamine—Nervousness—Epirubicin—thyroid cancer	0.000734	0.00106	CcSEcCtD
Galantamine—Back pain—Epirubicin—thyroid cancer	0.000732	0.00105	CcSEcCtD
Galantamine—Angiopathy—Doxorubicin—thyroid cancer	0.000729	0.00105	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000727	0.0214	CbGpPWpGaD
Galantamine—Muscle spasms—Epirubicin—thyroid cancer	0.000727	0.00105	CcSEcCtD
Galantamine—Immune system disorder—Doxorubicin—thyroid cancer	0.000726	0.00104	CcSEcCtD
Galantamine—Arrhythmia—Doxorubicin—thyroid cancer	0.000718	0.00103	CcSEcCtD
Galantamine—Vision blurred—Epirubicin—thyroid cancer	0.000713	0.00102	CcSEcCtD
Galantamine—Mental disorder—Doxorubicin—thyroid cancer	0.000704	0.00101	CcSEcCtD
Galantamine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000702	0.00101	CcSEcCtD
Galantamine—Malnutrition—Doxorubicin—thyroid cancer	0.0007	0.00101	CcSEcCtD
Galantamine—Anaemia—Epirubicin—thyroid cancer	0.000699	0.001	CcSEcCtD
Galantamine—Agitation—Epirubicin—thyroid cancer	0.000695	0.000999	CcSEcCtD
Galantamine—Flatulence—Doxorubicin—thyroid cancer	0.00069	0.000991	CcSEcCtD
Galantamine—Tension—Doxorubicin—thyroid cancer	0.000687	0.000987	CcSEcCtD
Galantamine—Dysgeusia—Doxorubicin—thyroid cancer	0.000685	0.000985	CcSEcCtD
Galantamine—Malaise—Epirubicin—thyroid cancer	0.000682	0.00098	CcSEcCtD
Galantamine—Nervousness—Doxorubicin—thyroid cancer	0.00068	0.000977	CcSEcCtD
Galantamine—Vertigo—Epirubicin—thyroid cancer	0.000679	0.000977	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—RET—thyroid cancer	0.000679	0.02	CbGpPWpGaD
Galantamine—Syncope—Epirubicin—thyroid cancer	0.000678	0.000975	CcSEcCtD
Galantamine—Back pain—Doxorubicin—thyroid cancer	0.000677	0.000973	CcSEcCtD
Galantamine—Muscle spasms—Doxorubicin—thyroid cancer	0.000673	0.000967	CcSEcCtD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—NRG1—thyroid cancer	0.000668	0.0197	CbGpPWpGaD
Galantamine—Palpitations—Epirubicin—thyroid cancer	0.000668	0.000961	CcSEcCtD
Galantamine—Loss of consciousness—Epirubicin—thyroid cancer	0.000665	0.000956	CcSEcCtD
Galantamine—Cough—Epirubicin—thyroid cancer	0.00066	0.000949	CcSEcCtD
Galantamine—Vision blurred—Doxorubicin—thyroid cancer	0.000659	0.000948	CcSEcCtD
Galantamine—Convulsion—Epirubicin—thyroid cancer	0.000655	0.000942	CcSEcCtD
Galantamine—Hypertension—Epirubicin—thyroid cancer	0.000653	0.000939	CcSEcCtD
Galantamine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000649	0.000933	CcSEcCtD
Galantamine—Anaemia—Doxorubicin—thyroid cancer	0.000647	0.00093	CcSEcCtD
Galantamine—Myalgia—Epirubicin—thyroid cancer	0.000644	0.000926	CcSEcCtD
Galantamine—Arthralgia—Epirubicin—thyroid cancer	0.000644	0.000926	CcSEcCtD
Galantamine—Chest pain—Epirubicin—thyroid cancer	0.000644	0.000926	CcSEcCtD
Galantamine—Agitation—Doxorubicin—thyroid cancer	0.000643	0.000924	CcSEcCtD
Galantamine—Anxiety—Epirubicin—thyroid cancer	0.000642	0.000922	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000639	0.000919	CcSEcCtD
Galantamine—Discomfort—Epirubicin—thyroid cancer	0.000636	0.000915	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000631	0.0186	CbGpPWpGaD
Galantamine—Malaise—Doxorubicin—thyroid cancer	0.000631	0.000907	CcSEcCtD
Galantamine—Dry mouth—Epirubicin—thyroid cancer	0.00063	0.000905	CcSEcCtD
Galantamine—Vertigo—Doxorubicin—thyroid cancer	0.000629	0.000904	CcSEcCtD
Galantamine—Syncope—Doxorubicin—thyroid cancer	0.000627	0.000902	CcSEcCtD
Galantamine—Confusional state—Epirubicin—thyroid cancer	0.000622	0.000895	CcSEcCtD
Galantamine—Palpitations—Doxorubicin—thyroid cancer	0.000618	0.000889	CcSEcCtD
Galantamine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000615	0.000884	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000614	0.0181	CbGpPWpGaD
Galantamine—Cough—Doxorubicin—thyroid cancer	0.000611	0.000878	CcSEcCtD
Galantamine—Shock—Epirubicin—thyroid cancer	0.000607	0.000873	CcSEcCtD
Galantamine—Convulsion—Doxorubicin—thyroid cancer	0.000606	0.000872	CcSEcCtD
Galantamine—Nervous system disorder—Epirubicin—thyroid cancer	0.000605	0.00087	CcSEcCtD
Galantamine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000604	0.000869	CcSEcCtD
Galantamine—Hypertension—Doxorubicin—thyroid cancer	0.000604	0.000869	CcSEcCtD
Galantamine—Tachycardia—Epirubicin—thyroid cancer	0.000602	0.000866	CcSEcCtD
Galantamine—Skin disorder—Epirubicin—thyroid cancer	0.000599	0.000862	CcSEcCtD
Galantamine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000597	0.000858	CcSEcCtD
Galantamine—Chest pain—Doxorubicin—thyroid cancer	0.000596	0.000856	CcSEcCtD
Galantamine—Arthralgia—Doxorubicin—thyroid cancer	0.000596	0.000856	CcSEcCtD
Galantamine—Myalgia—Doxorubicin—thyroid cancer	0.000596	0.000856	CcSEcCtD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—NRAS—thyroid cancer	0.000594	0.0175	CbGpPWpGaD
Galantamine—Anxiety—Doxorubicin—thyroid cancer	0.000594	0.000853	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000592	0.000851	CcSEcCtD
Galantamine—Discomfort—Doxorubicin—thyroid cancer	0.000589	0.000846	CcSEcCtD
Galantamine—Anorexia—Epirubicin—thyroid cancer	0.000588	0.000846	CcSEcCtD
Galantamine—Dry mouth—Doxorubicin—thyroid cancer	0.000583	0.000838	CcSEcCtD
Galantamine—Hypotension—Epirubicin—thyroid cancer	0.000577	0.000829	CcSEcCtD
Galantamine—Confusional state—Doxorubicin—thyroid cancer	0.000576	0.000828	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000562	0.000808	CcSEcCtD
Galantamine—Shock—Doxorubicin—thyroid cancer	0.000562	0.000808	CcSEcCtD
Galantamine—Nervous system disorder—Doxorubicin—thyroid cancer	0.00056	0.000805	CcSEcCtD
Galantamine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000559	0.000804	CcSEcCtD
Galantamine—Insomnia—Epirubicin—thyroid cancer	0.000558	0.000803	CcSEcCtD
Galantamine—Tachycardia—Doxorubicin—thyroid cancer	0.000557	0.000801	CcSEcCtD
Galantamine—Skin disorder—Doxorubicin—thyroid cancer	0.000555	0.000797	CcSEcCtD
Galantamine—Paraesthesia—Epirubicin—thyroid cancer	0.000554	0.000797	CcSEcCtD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—RET—thyroid cancer	0.000553	0.0163	CbGpPWpGaD
Galantamine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000552	0.000794	CcSEcCtD
Galantamine—Somnolence—Epirubicin—thyroid cancer	0.000549	0.000789	CcSEcCtD
Galantamine—Anorexia—Doxorubicin—thyroid cancer	0.000544	0.000783	CcSEcCtD
Galantamine—Dyspepsia—Epirubicin—thyroid cancer	0.000543	0.000781	CcSEcCtD
Galantamine—Decreased appetite—Epirubicin—thyroid cancer	0.000537	0.000771	CcSEcCtD
Galantamine—Hypotension—Doxorubicin—thyroid cancer	0.000534	0.000767	CcSEcCtD
Galantamine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000533	0.000766	CcSEcCtD
Galantamine—Fatigue—Epirubicin—thyroid cancer	0.000532	0.000765	CcSEcCtD
Galantamine—Constipation—Epirubicin—thyroid cancer	0.000528	0.000759	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00052	0.000748	CcSEcCtD
Galantamine—Insomnia—Doxorubicin—thyroid cancer	0.000517	0.000743	CcSEcCtD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000515	0.0152	CbGpPWpGaD
Galantamine—Paraesthesia—Doxorubicin—thyroid cancer	0.000513	0.000737	CcSEcCtD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—KRAS—thyroid cancer	0.000511	0.0151	CbGpPWpGaD
Galantamine—Feeling abnormal—Epirubicin—thyroid cancer	0.000509	0.000731	CcSEcCtD
Galantamine—Somnolence—Doxorubicin—thyroid cancer	0.000508	0.00073	CcSEcCtD
Galantamine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000505	0.000726	CcSEcCtD
Galantamine—Dyspepsia—Doxorubicin—thyroid cancer	0.000503	0.000723	CcSEcCtD
Galantamine—Decreased appetite—Doxorubicin—thyroid cancer	0.000496	0.000714	CcSEcCtD
Galantamine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000493	0.000709	CcSEcCtD
Galantamine—Fatigue—Doxorubicin—thyroid cancer	0.000492	0.000708	CcSEcCtD
Galantamine—Constipation—Doxorubicin—thyroid cancer	0.000488	0.000702	CcSEcCtD
Galantamine—Abdominal pain—Epirubicin—thyroid cancer	0.000488	0.000701	CcSEcCtD
Galantamine—Body temperature increased—Epirubicin—thyroid cancer	0.000488	0.000701	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000485	0.0143	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000483	0.0142	CbGpPWpGaD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000476	0.014	CbGpPWpGaD
Galantamine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000471	0.000677	CcSEcCtD
Galantamine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000467	0.000671	CcSEcCtD
Galantamine—Hypersensitivity—Epirubicin—thyroid cancer	0.000455	0.000654	CcSEcCtD
Galantamine—Body temperature increased—Doxorubicin—thyroid cancer	0.000451	0.000649	CcSEcCtD
Galantamine—Abdominal pain—Doxorubicin—thyroid cancer	0.000451	0.000649	CcSEcCtD
Galantamine—Asthenia—Epirubicin—thyroid cancer	0.000443	0.000637	CcSEcCtD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—HRAS—thyroid cancer	0.000434	0.0128	CbGpPWpGaD
Galantamine—Diarrhoea—Epirubicin—thyroid cancer	0.000422	0.000607	CcSEcCtD
Galantamine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000421	0.000605	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000419	0.0124	CbGpPWpGaD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000416	0.0123	CbGpPWpGaD
Galantamine—Asthenia—Doxorubicin—thyroid cancer	0.00041	0.000589	CcSEcCtD
Galantamine—Dizziness—Epirubicin—thyroid cancer	0.000408	0.000587	CcSEcCtD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000394	0.0116	CbGpPWpGaD
Galantamine—Vomiting—Epirubicin—thyroid cancer	0.000392	0.000564	CcSEcCtD
Galantamine—Diarrhoea—Doxorubicin—thyroid cancer	0.000391	0.000562	CcSEcCtD
Galantamine—Rash—Epirubicin—thyroid cancer	0.000389	0.000559	CcSEcCtD
Galantamine—Dermatitis—Epirubicin—thyroid cancer	0.000389	0.000559	CcSEcCtD
Galantamine—Headache—Epirubicin—thyroid cancer	0.000387	0.000556	CcSEcCtD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—AKT1—thyroid cancer	0.000384	0.0113	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000382	0.0113	CbGpPWpGaD
Galantamine—Dizziness—Doxorubicin—thyroid cancer	0.000378	0.000543	CcSEcCtD
Galantamine—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000377	0.0111	CbGpPWpGaD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000376	0.0111	CbGpPWpGaD
Galantamine—Nausea—Epirubicin—thyroid cancer	0.000367	0.000527	CcSEcCtD
Galantamine—Vomiting—Doxorubicin—thyroid cancer	0.000363	0.000522	CcSEcCtD
Galantamine—Rash—Doxorubicin—thyroid cancer	0.00036	0.000518	CcSEcCtD
Galantamine—Dermatitis—Doxorubicin—thyroid cancer	0.00036	0.000517	CcSEcCtD
Galantamine—CHRNA9—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000358	0.0105	CbGpPWpGaD
Galantamine—Headache—Doxorubicin—thyroid cancer	0.000358	0.000514	CcSEcCtD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000354	0.0104	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000342	0.0101	CbGpPWpGaD
Galantamine—Nausea—Doxorubicin—thyroid cancer	0.000339	0.000488	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000332	0.00977	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000313	0.00922	CbGpPWpGaD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000299	0.00881	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—NRAS—thyroid cancer	0.000299	0.0088	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000296	0.00874	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000291	0.00859	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000283	0.00834	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—BRAF—thyroid cancer	0.000274	0.00808	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00027	0.00797	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000266	0.00784	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000263	0.00776	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—KRAS—thyroid cancer	0.000257	0.00758	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—BRAF—thyroid cancer	0.00024	0.00706	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000229	0.00676	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—BRAF—thyroid cancer	0.000227	0.00669	CbGpPWpGaD
Galantamine—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000225	0.00664	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000225	0.00662	CbGpPWpGaD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000219	0.00645	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—HRAS—thyroid cancer	0.000219	0.00644	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—BRAF—thyroid cancer	0.000217	0.00639	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000209	0.00617	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000207	0.00611	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—BRAF—thyroid cancer	0.000204	0.006	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—PPARG—thyroid cancer	0.000202	0.00596	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.0002	0.00591	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000199	0.00587	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000198	0.00583	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—AKT1—thyroid cancer	0.000193	0.00569	CbGpPWpGaD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000191	0.00564	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000189	0.00558	CbGpPWpGaD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000181	0.00534	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.00018	0.0053	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000178	0.00524	CbGpPWpGaD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000173	0.0051	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—BRAF—thyroid cancer	0.000172	0.00507	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000169	0.00498	CbGpPWpGaD
Galantamine—CHRNA9—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000165	0.00485	CbGpPWpGaD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000163	0.00479	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000162	0.00478	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000157	0.00464	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000156	0.00459	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000153	0.00452	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—CCND1—thyroid cancer	0.000152	0.00449	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—BRAF—thyroid cancer	0.000152	0.00447	CbGpPWpGaD
Galantamine—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000149	0.00438	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000147	0.00432	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000144	0.00424	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000142	0.0042	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—PTEN—thyroid cancer	0.000139	0.00409	CbGpPWpGaD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000137	0.00405	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000137	0.00405	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000137	0.00403	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000136	0.00402	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000135	0.00398	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000134	0.00394	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000133	0.00391	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000131	0.00386	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.00013	0.00383	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000127	0.00375	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—HRAS—thyroid cancer	0.000126	0.00371	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000122	0.0036	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000121	0.00357	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—BRAF—thyroid cancer	0.000121	0.00355	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—BRAF—thyroid cancer	0.000119	0.00352	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000111	0.00328	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.00011	0.00325	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—HRAS—thyroid cancer	0.00011	0.00325	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—BRAF—thyroid cancer	0.000109	0.00322	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MINPP1—thyroid cancer	0.000106	0.00312	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—HRAS—thyroid cancer	0.000104	0.00308	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—BRAF—thyroid cancer	0.000104	0.00305	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000103	0.00304	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—BRAF—thyroid cancer	0.000102	0.00302	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—HRAS—thyroid cancer	9.96e-05	0.00294	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—BRAF—thyroid cancer	9.74e-05	0.00287	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	9.62e-05	0.00284	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	9.53e-05	0.00281	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—TP53—thyroid cancer	9.47e-05	0.00279	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MINPP1—thyroid cancer	9.45e-05	0.00279	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—HRAS—thyroid cancer	9.37e-05	0.00276	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—HRAS—thyroid cancer	9.1e-05	0.00268	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NDUFA13—thyroid cancer	9.01e-05	0.00266	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	8.98e-05	0.00265	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	8.93e-05	0.00263	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	8.71e-05	0.00257	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CHST14—thyroid cancer	8.47e-05	0.0025	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—BRAF—thyroid cancer	8.44e-05	0.00249	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	8.27e-05	0.00244	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	8.18e-05	0.00241	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NDUFA13—thyroid cancer	8.04e-05	0.00237	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—HRAS—thyroid cancer	7.92e-05	0.00233	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—BRAF—thyroid cancer	7.86e-05	0.00232	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	7.77e-05	0.00229	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CHST14—thyroid cancer	7.56e-05	0.00223	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PTEN—thyroid cancer	7.45e-05	0.0022	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	7.28e-05	0.00215	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—HRAS—thyroid cancer	7.23e-05	0.00213	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—HRAS—thyroid cancer	7.16e-05	0.00211	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—BRAF—thyroid cancer	7.01e-05	0.00207	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—HRAS—thyroid cancer	6.97e-05	0.00205	CbGpPWpGaD
Galantamine—ACHE—Metabolism—HPGD—thyroid cancer	6.83e-05	0.00201	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	6.74e-05	0.00199	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PTEN—thyroid cancer	6.65e-05	0.00196	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	6.59e-05	0.00194	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—HRAS—thyroid cancer	6.55e-05	0.00193	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—HRAS—thyroid cancer	6.21e-05	0.00183	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—HRAS—thyroid cancer	6.15e-05	0.00181	CbGpPWpGaD
Galantamine—BCHE—Metabolism—HPGD—thyroid cancer	6.09e-05	0.0018	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—BRAF—thyroid cancer	6.02e-05	0.00178	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	5.95e-05	0.00175	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	5.92e-05	0.00174	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.84e-05	0.00172	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	5.75e-05	0.00169	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—HRAS—thyroid cancer	5.54e-05	0.00163	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.54e-05	0.00163	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—HRAS—thyroid cancer	5.49e-05	0.00162	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—BRAF—thyroid cancer	5.37e-05	0.00158	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.07e-05	0.00149	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—HRAS—thyroid cancer	5.02e-05	0.00148	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.94e-05	0.00146	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—HRAS—thyroid cancer	4.76e-05	0.0014	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—HRAS—thyroid cancer	4.71e-05	0.00139	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—HRAS—thyroid cancer	4.48e-05	0.00132	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	4.41e-05	0.0013	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MINPP1—thyroid cancer	4.35e-05	0.00128	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TPR—thyroid cancer	3.92e-05	0.00116	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.92e-05	0.00116	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—HRAS—thyroid cancer	3.88e-05	0.00114	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—RXRA—thyroid cancer	3.87e-05	0.00114	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PRKAR1A—thyroid cancer	3.86e-05	0.00114	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	3.7e-05	0.00109	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.61e-05	0.00107	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TPR—thyroid cancer	3.5e-05	0.00103	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.5e-05	0.00103	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CHST14—thyroid cancer	3.47e-05	0.00102	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PRKAR1A—thyroid cancer	3.44e-05	0.00101	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.31e-05	0.000976	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—HRAS—thyroid cancer	3.22e-05	0.00095	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.12e-05	0.000919	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SLC5A5—thyroid cancer	2.94e-05	0.000865	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MINPP1—thyroid cancer	2.84e-05	0.000837	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—HPGD—thyroid cancer	2.8e-05	0.000825	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—HRAS—thyroid cancer	2.77e-05	0.000816	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.75e-05	0.000811	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SLC5A5—thyroid cancer	2.62e-05	0.000772	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—HRAS—thyroid cancer	2.47e-05	0.000728	CbGpPWpGaD
Galantamine—ACHE—Metabolism—RXRA—thyroid cancer	2.47e-05	0.000727	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.45e-05	0.000723	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.42e-05	0.000712	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.4e-05	0.000707	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CHST14—thyroid cancer	2.27e-05	0.00067	CbGpPWpGaD
Galantamine—BCHE—Metabolism—RXRA—thyroid cancer	2.2e-05	0.000649	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.14e-05	0.000631	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HPGD—thyroid cancer	1.83e-05	0.00054	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TPR—thyroid cancer	1.61e-05	0.000474	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.58e-05	0.000466	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PPARG—thyroid cancer	1.56e-05	0.000459	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PPARG—thyroid cancer	1.39e-05	0.000409	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTGS2—thyroid cancer	1.23e-05	0.000361	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.2e-05	0.000355	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTGS2—thyroid cancer	1.09e-05	0.000322	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTEN—thyroid cancer	1.07e-05	0.000315	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TPR—thyroid cancer	1.05e-05	0.00031	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.03e-05	0.000305	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—RXRA—thyroid cancer	1.01e-05	0.000298	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTEN—thyroid cancer	9.53e-06	0.000281	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	7.87e-06	0.000232	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—RXRA—thyroid cancer	6.61e-06	0.000195	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PPARG—thyroid cancer	6.39e-06	0.000188	CbGpPWpGaD
Galantamine—ACHE—Metabolism—AKT1—thyroid cancer	6.16e-06	0.000181	CbGpPWpGaD
Galantamine—BCHE—Metabolism—AKT1—thyroid cancer	5.49e-06	0.000162	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTGS2—thyroid cancer	5.03e-06	0.000148	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTEN—thyroid cancer	4.38e-06	0.000129	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PPARG—thyroid cancer	4.18e-06	0.000123	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.29e-06	9.68e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTEN—thyroid cancer	2.87e-06	8.44e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AKT1—thyroid cancer	2.53e-06	7.44e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AKT1—thyroid cancer	1.65e-06	4.87e-05	CbGpPWpGaD
